| Species |
Human |
| Protein Construction |
CTLA-4/CD152 (Lys36-Asp161)
Accession # P16410 |
His |
Avi |
| N-term |
|
C-term |
|
| Conjugate |
Biotin |
| Purity |
> 95% as determined by BisTris PAGE
> 95% as determined by HPLC |
| Endotoxin Level |
Less than 1EU per μg by the LAL method. |
| Biological Activity |
Measured by its binding ability in a functional ELISA. Immobilized CTLA-4/CD152[Biotin], His & Avi, Human at 1μg/ml (100μl/well) on the streptavidin precoated plate (5μg/ml) can bind Human B71, hFc Tag. Test result was comparable to standard batch. |
| Expression System |
HEK293 |
| Theoretical Molecular Weight |
16.3 kDa |
| Apparent Molecular Weight |
Due to glycosylation, the protein migrates to 25-30 kDa based on Bis-Tris PAGE result. |
| Formulation |
Lyophilized from 0.22μm filtered solution in PBS (pH 7.4). |
| Reconstitution |
Centrifuge the tube before opening. Reconstituting to a concentration more than 100 μg/ml is recommended. Dissolve the lyophilized protein in distilled water. |
| Storage & Stability |
Upon receiving, the product remains stable up to 6 months at -20 °C or below. Upon reconstitution, the product should be stable for 3 months at -80 °C. Avoid repeated freeze-thaw cycles. |
| Target Background |
CTLA-4 (cytotoxic T-lymphocyte-associated protein 4), also known as CD152, is a protein receptor that, functioning as an immune checkpoint, downregulates immune responses.CTLA4 is constitutively expressed in regulatory T cells but only upregulated in conventional T cells after activation – a phenomenon which is particularly notable in cancers. It acts as an 'off' switch when bound to CD80 or CD86 on the surface of antigen-presenting cells. |
| Synonyms |
CTLA4; CD152; ICOS; CELIAC3; GRD4; GSE; ALPS5; IDDM12 |
For research use only. Not intended for human or animal clinical trials, therapeutic or diagnostic use.
